Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance - Wikidata - wikimedia - TriplyDB

Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance

Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance

http://www.wikidata.org/entity/Q28219288

about

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis Blood cells: an historical account of the roles of purinergic signalling Aspirin resistance: current status and role of tailored therapy Acetylsalicylic acid resistance and clinical outcome--the Hobikoglu study is worth noting Agonist-inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia.Antiplatelet and anticoagulant drugs in interventional radiology.Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin Implementing genotype-guided antithrombotic therapy.Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study Aspirin resistance: Fact or fiction? A point of view.Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations.Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy.Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients.Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients Pharmacogenomics of platelet responsiveness to aspirin.Pharmacogenetics of aspirin resistance: a comprehensive systematic review.Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study Update on oral antiplatelet therapy: principles, problems and promises.Cangrelor: a novel P2Y12 receptor antagonist.Aspirin resistance in patients with type II diabetes mellitus.Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Interactions among COX-2, GPIIIa and P2Y1 variants are associated with aspirin responsiveness and adverse events in patients with ischemic stroke.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.Functional testing methods for the antiplatelet effects of aspirin.The pharmacogenetics of antiplatelet agents: towards personalized therapy?A contemporary viewpoint on 'aspirin resistance'.Advances in monitoring of aspirin therapy.Overcoming aspirin treatment failure in diabetes.Monitoring aspirin and clopidogrel response: testing controversies and recommendations.Genetics of platelet inhibitor treatment Aspirin resistance: a clinical review focused on the most common cause, noncompliance.Cardiovascular pharmacology core reviews: aspirin.Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention.Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery

P2860

Q24645413-31367742-75D2-4DA1-9E6D-9AB63CADC126 Q26799623-45A14340-D2A9-497A-B602-C67C15C0F3B3 Q26851367-EBC02337-04C4-4C1D-B8F6-B9304AEF7EF1 Q28220410-4DABA6D4-A4C2-4F72-A740-5ABEA652AE05 Q33376011-CC2AEB94-D88E-4844-ABB3-C0C7D3775603 Q33395898-B04634CD-9410-483D-B9B5-D4BAE0CAF822 Q33399119-A8B90C03-A9AD-4812-B149-DC035A738E1E Q33791290-ABC0072F-92E2-4C8D-ADA6-53DE4BB34737 Q33837587-F79BD48E-50A0-464A-8740-271CF45D3CE7 Q33990428-340EAC4B-E54F-472F-B36D-7AFE18DEF2F1 Q34023032-441E9FD2-E0DA-4CC3-A90C-083D3C689840 Q34389630-E7330506-9641-4519-9B1E-BE744C60287A Q35373683-A388ECAA-46C1-4DD3-B292-3D822788DB2E Q35735264-14F76EC4-64B3-463B-B84A-F0BF5EA4602A Q35755253-29247165-16A4-46E7-A839-62E46D36FAFB Q35883494-FBCE5B09-305B-4520-AE4B-88E168C68E01 Q35916268-34870F16-434B-4059-815B-498C91AA7771 Q36111366-ACB89D45-A370-4DC9-929E-3410BF5C4782 Q36244656-D4C4C4AA-1F44-485D-A899-9370AC9338CA Q36881941-117A613E-3135-4977-9093-917AF96E88D9 Q36989841-E8615C7B-FBD8-463D-A239-A0A3D37F6B58 Q37145122-A957E940-623C-4D4E-8CA0-D54D7292AA80 Q37234897-053499E9-97C2-4C49-BFD8-53730BC15ACB Q37486605-1EB3F6B8-EFBE-4FF8-998D-382D93C6E940 Q37551923-945494FA-72B9-4F23-8BF7-EFD93E8D00E8 Q37564161-6072E057-EFC7-48CA-B33A-042A36C7750A Q37629641-AB2994DD-5644-4DC3-9385-DA0F1E6041E8 Q37698588-BDA219E2-EAD7-4098-B303-F25C57717AEF Q37797795-DDCC6CB6-1D67-49AC-831D-F4727703D036 Q37841562-472C78BB-2A52-4EB0-A0D6-322C903F7441 Q37913976-49627857-F053-4B65-AF66-380FDDB80AED Q37989558-0B159C96-78BC-456D-943E-D7C949179E3D Q38032895-F31766E1-189F-41B8-B3E8-3B5BABA0D839 Q38055245-E587FE72-6EEB-476D-B7CB-CF66D9850943 Q38099235-EDB7CD13-71D6-445D-AD79-851483F59ED5 Q38131848-5B898157-9F8B-4A1A-8EE7-61813CE83B88 Q38132148-C1E7E5B0-8751-4001-BF75-71E1C78AEEA3 Q38140795-BE456EFC-BC74-40D7-8E76-B8CAB2E0FDDC Q38197732-15498BE2-09E2-44F5-8DA8-9DBC801ABF97 Q38543604-EF33B8E4-3775-4C93-AC03-587FE0C5F734

P2860

Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance

http://www.wikidata.org/entity/Q28219288

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@ast

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@en

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@nl

type

label

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@ast

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@en

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@nl

prefLabel

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@ast

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@en

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@nl

P1433

Q28219288-232B4BB4-7871-4DA9-AB3B-2CB04489749D

P1476

Q28219288-549E5D71-C6A8-4C85-8AD4-6C6AFA904AF7

P2093

Q28219288-13846586-0ACB-486F-BFF6-14FE767AF951

Q28219288-14EE8696-072A-4DA4-A099-8374F1FAE036

Q28219288-28D7249B-95FD-480D-B606-B2B3A95489AD

Q28219288-5E2734AA-A105-4BD6-B7E0-123937221FB6

Q28219288-93B24D87-D2D2-42CA-A3DB-30FDC1EA0549

Q28219288-9D8DEEB1-B68D-48CA-9772-B3FE909E6A25

P304

Q28219288-45A835EF-DA3D-4CBA-B062-12060CBD09CD

P31

Q28219288-87A34A60-62A4-4866-918D-413C9327671A

P3181

Q28219288-E9A8FBB1-2AE9-4AAD-9A23-DC6DD26DD263

P356

Q28219288-B1808A3F-64FA-442E-A90A-496F4AE99FF7

P407

Q28219288-272CE719-DFC9-4057-B5E7-C2E8125C969C

P433

Q28219288-41177BCF-43FB-4C30-82B7-C11C017375E5

P478

Q28219288-0112C566-F4E9-4885-A660-771273761FF5

P50

Q28219288-FB7BB4BF-18A9-4D04-9151-6BD2567BBF4E

P577

Q28219288-D67A043C-8E20-484C-98B1-C9EF63A5301E

P698

Q28219288-853EF858-3C9E-46D9-8F25-B2DB60CDF4F5

P921

Q28219288-0B112A29-3863-4CF7-9BAF-AE3B598D502A

Q28219288-E3179C76-25D9-4727-B4AE-F8832DE24EFE

P3181

P356

CIRCULATIONAHA.105.596627

P1433

P1476

Residual arachidonic acid-indu ...... nt study of aspirin resistance

@en

P2093

Alan D Michelson

http://www.w3.org/2001/XMLSchema#string

Andrew L Frelinger

http://www.w3.org/2001/XMLSchema#string

Marc R Barnard

http://www.w3.org/2001/XMLSchema#string

Mark I Furman

http://www.w3.org/2001/XMLSchema#string

Marsha L Fox

http://www.w3.org/2001/XMLSchema#string

Youfu Li

http://www.w3.org/2001/XMLSchema#string

P304

2888-2896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2951750

http://www.w3.org/2001/XMLSchema#string

P356

10.1161/CIRCULATIONAHA.105.596627

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Matthew D. Linden

P577

2006-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16785341

http://www.w3.org/2001/XMLSchema#string

P921